Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Canakinumab in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium [MPN-RC 122]

NCT05467800 is registered in ClinicalTrials.gov with John Mascarenhas as lead sponsor.

NCT NCT05467800
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05467800 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Canakinumab in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium [MPN-RC 122]
Lead sponsor
John Mascarenhas
Phase
Phase 2
Overall status
Active, not recruiting
Start date
August 2, 2022
Completion date
July 1, 2027
Enrollment
14 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

et-mf, post-essential thrombocythemia myelofibrosis, post-polycythemia vera related myelofibrosis, primary myelofibrosis, pv-mf